CD8A and melanoma: In clinical trials of patients with advanced malignant melanoma, combined treatment with the TLR9 agonists SD-101 and pembrolizumab resulted in increased type I IFN production and CD8+ T-cell infiltration and potentially improved clinical efficacy 102.